Pancreatic Cancer Research

ResearcherNational Taiwan UniversityActive in the last 2 years

Yu‐Wen Tien

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9126-2705; OpenAlex author ID A5012873714. Sources: ClinicalTrials.gov.

Their work

Papers
42 (first author 2, last author 2)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
1
Collaborators
75
Papers, trials and grants by year

2009: 1 trial · 2010: none · 2011: 2 papers · 2012: 2 papers · 2013: 1 paper · 2014: 2 papers · 2015: 1 paper · 2016: 6 papers · 2017: 1 paper, 1 trial · 2018: 4 papers · 2019: 4 papers · 2020: 2 papers · 2021: 8 papers · 2022: 3 papers · 2023: 2 papers · 2024: 3 papers · 2025: 1 paper

Papers 42

  1. Correction: SEMA7A-mediated juxtacrine stimulation of IGFBP-3 upregulates IL-17RB at pancreatic cancer invasive front. Co-author DOI 10.1038/s41417-024-00857-6↗
  2. Adding-on nivolumab to chemotherapy-stabilized patients is associated with improved survival in advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00262-024-03821-3↗
  3. Changes in nutritional status and fatigue and their associations with quality of life in patients with pancreatic cancer after surgery: A 12-month longitudinal… Co-author DOI 10.1016/j.apnr.2024.151858↗
  4. SEMA7A-mediated juxtacrine stimulation of IGFBP-3 upregulates IL-17RB at pancreatic cancer invasive front. Co-author DOI 10.1038/s41417-024-00849-6↗
  5. Role of preoperative malnutrition and symptom severity in anorexia-cachexia-related quality of life in patients with operable pancreatic cancer. Co-author DOI 10.1016/j.ejon.2023.102352↗
  6. Diverse genetic spectrum among patients who met the criteria of hereditary breast, ovarian and pancreatic cancer syndrome. First author DOI 10.3802/jgo.2023.34.e66↗
  7. The role of S100A9 in the interaction between pancreatic ductal adenocarcinoma cells and stromal cells. Co-author DOI 10.1007/s00262-021-03026-y↗
  8. Distinct Survival Outcomes in Subgroups of Stage III Pancreatic Cancer Patients: Taiwan Cancer Registry and Surveillance, Epidemiology and End Results registry. Last author DOI 10.1245/s10434-021-11030-w↗
  9. ASO Author Reflections: Identification of Prognostic Factors for Stage-III Pancreatic Ductal Adenocarcinoma patients. Co-author DOI 10.1245/s10434-021-11041-7↗
  10. Preoperative sarcopenia is associated with poor overall survival in pancreatic cancer patients following pancreaticoduodenectomy. Co-author DOI 10.1007/s00330-020-07294-7↗
  11. C1GALT1 high expression is associated with poor survival of patients with pancreatic ductal adenocarcinoma and promotes cell invasiveness through integrin αv. Co-author DOI 10.1038/s41388-020-01594-4↗
  12. Negative prognostic implications of splenomegaly in nivolumab-treated advanced or recurrent pancreatic adenocarcinoma. Co-author DOI 10.1080/2162402x.2021.1973710↗
  13. Characterization of initial key steps of IL-17 receptor B oncogenic signaling for targeted therapy of pancreatic cancer. Co-author DOI 10.1126/scitranslmed.abc2823↗
  14. Contribution of nuclear BCL10 expression to tumor progression and poor prognosis of advanced and/or metastatic pancreatic ductal adenocarcinoma by activating N… Co-author DOI 10.1186/s12935-021-02143-z↗
  15. Determinants of Quality of Life in Individuals With a Dual Diagnosis of Resectable Pancreatic Cancer and Diabetes Mellitus. Co-author DOI 10.1188/21.onf.390-402↗
  16. Competing Risk Analysis of Outcomes of Unresectable Pancreatic Cancer Patients Undergoing Definitive Radiotherapy. Co-author DOI 10.3389/fonc.2021.730646↗
  17. Metabolic Alterations in Pancreatic Cancer Detected by In Vivo 1H-MR Spectroscopy: Correlation with Normal Pancreas, PET Metabolic Activity, Clinical Stages, a… Co-author DOI 10.3390/diagnostics11091541↗
  18. Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients. Co-author DOI 10.1016/j.jfma.2019.01.015↗
  19. S-1-Associated Hypertriglyceridemia in a Patient With Pancreatic Adenocarcinoma. Co-author DOI 10.1200/jop.19.00204↗
  20. Prospective comparison of (4S)-4-(3-18F-fluoropropyl)-L-glutamate versus 18F-fluorodeoxyglucose PET/CT for detecting metastases from pancreatic ductal adenocar… Last author DOI 10.1007/s00259-018-4251-5↗
  21. Biomaterial substrate-derived compact cellular spheroids mimicking the behavior of pancreatic cancer and microenvironment. Co-author DOI 10.1016/j.biomaterials.2019.05.013↗
  22. Lymphatic vessel remodeling and invasion in pancreatic cancer progression. Co-author DOI 10.1016/j.ebiom.2019.08.044↗
  23. Postoperative Imaging and Tumor Marker Surveillance in Resected Pancreatic Cancer. Co-author DOI 10.3390/jcm8081115↗
  24. Multiparametric PET/MR imaging biomarkers are associated with overall survival in patients with pancreatic cancer. First author DOI 10.1007/s00259-018-3960-0↗
  25. Pyruvate kinase M2 promotes pancreatic ductal adenocarcinoma invasion and metastasis through phosphorylation and stabilization of PAK2 protein. Co-author DOI 10.1038/s41388-017-0086-y↗
  26. Silencing of MUC20 suppresses the malignant character of pancreatic ductal adenocarcinoma cells through inhibition of the HGF/MET pathway. Co-author DOI 10.1038/s41388-018-0403-0↗
  27. Cellular 5-hydroxylmethylcytosine content determines tumorigenic potential and prognosis of pancreatic ductal adenocarcinoma. Co-author PMID 30662811↗
  28. Association of MDM2 expression with shorter progression-free survival and overall survival in patients with advanced pancreatic cancer treated with gemcitabine… Co-author DOI 10.1371/journal.pone.0180628↗
  29. Targeted Delivery of C/EBPα -saRNA by Pancreatic Ductal Adenocarcinoma-specific RNA Aptamers Inhibits Tumor Growth In Vivo. Co-author DOI 10.1038/mt.2016.60↗
  30. A High Circulating Tumor Cell Count in Portal Vein Predicts Liver Metastasis From Periampullary or Pancreatic Cancer: A High Portal Venous CTC Count Predicts L… Co-author DOI 10.1097/md.0000000000003407↗
  31. Association of radiotherapy with favorable prognosis in daily clinical practice for treatment of locally advanced and metastatic pancreatic cancer. Co-author DOI 10.1111/jgh.13395↗
  32. Inhibition of Prostaglandin Reductase 2, a Putative Oncogene Overexpressed in Human Pancreatic Adenocarcinoma, Induces Oxidative Stress-Mediated Cell Death Inv… Co-author DOI 10.1371/journal.pone.0147390↗
  33. Clinical Significance of Circulating Tumor Microemboli as a Prognostic Marker in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1373/clinchem.2015.248260↗
  34. Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer. Co-author DOI 10.3748/wjg.v22.i32.7275↗
  35. Targeting IL-17B-IL-17RB signaling with an anti-IL-17RB antibody blocks pancreatic cancer metastasis by silencing multiple chemokines. Co-author DOI 10.1084/jem.20141702↗
  36. Increase diagnostic accuracy in differentiating focal type autoimmune pancreatitis from pancreatic cancer with combined serum IgG4 and CA19-9 levels. Co-author DOI 10.1016/j.pan.2014.07.010↗
  37. Comparison and validation of International Consensus Diagnostic Criteria for diagnosis of autoimmune pancreatitis from pancreatic cancer in a Taiwanese cohort. Co-author DOI 10.1136/bmjopen-2014-005900↗
  38. Nuclear expression of glioma-associated oncogene homolog 1 and nuclear factor-κB is associated with a poor prognosis of pancreatic cancer. Co-author DOI 10.1159/000353452↗
  39. CXCR4 expression predicts early liver recurrence and poor survival after resection of pancreatic adenocarcinoma. Co-author DOI 10.1038/ctg.2012.18↗
  40. SOX4 transcriptionally regulates multiple SEMA3/plexin family members and promotes tumor growth in pancreatic cancer. Co-author DOI 10.1371/journal.pone.0048637↗
  41. Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced… Co-author DOI 10.1016/j.ijrobp.2010.10.034↗
  42. Inferior survival of advanced pancreatic cancer patients who received gemcitabine-based chemotherapy but did not participate in clinical trials. Co-author DOI 10.1159/000330817↗

Trials 2

  1. S-1, Irinotecan, and Oxaliplatin in Locally-Advanced Pancreatic Cancer Principal investigator NCT03316326↗
  2. A Phase III Study of Pancreatic Cancer Principal investigator NCT00994721↗

Closest collaborators

The 25 strongest of 75 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shih‐Hung Yang · 15 shared papers, 2011–2024 · strength 1.56
  2. Sung‐Hsin Kuo · 12 shared papers, 2011–2024 · strength 1.30
  3. Ming‐Chu Chang · 11 shared papers, 2011–2025 · strength 1.04
  4. Yu‐Ting Chang · 10 shared papers, 2014–2025 · strength 1.02
  5. Ann‐Lii Cheng · 10 shared papers, 2011–2024 · strength 0.92
  6. Bang‐Bin Chen · 6 shared papers, 2018–2024 · strength 0.85
  7. Kun‐Huei Yeh · 6 shared papers, 2016–2024 · strength 0.75
  8. Ting‐Chun Kuo · 7 shared papers, 2016–2021 · strength 0.66
  9. Yun-Jen Chou · 3 shared papers, 2021–2024 · strength 0.62
  10. Shiow‐Ching Shun · 3 shared papers, 2021–2024 · strength 0.62
  11. Y.M. Chen · 4 shared papers, 2018–2025 · strength 0.61
  12. Chun‐Mei Hu · 4 shared papers, 2018–2025 · strength 0.61
  13. Tzu‐Pin Lu · 3 shared papers, 2021–2022 · strength 0.54
  14. Jhe‐Cyuan Guo · 5 shared papers, 2016–2020 · strength 0.45
  15. Sui-Chih Tien · 2 shared papers, 2024–2025 · strength 0.42
  16. Hsuan‐Yu Peng · 2 shared papers, 2024–2025 · strength 0.42
  17. Amrita Sengupta Chattopadhyay · 2 shared papers, 2022 · strength 0.38
  18. Hsuan‐Ju Kuo · 2 shared papers, 2021–2023 · strength 0.38
  19. Yung‐Ming Jeng · 5 shared papers, 2015–2021 · strength 0.37
  20. Mei‐Fang Cheng · 4 shared papers, 2016–2021 · strength 0.36
  21. Wen‐Hwa Lee · 5 shared papers, 2015–2021 · strength 0.33
  22. Ling-Fang Hsu · 1 shared paper, 2024 · strength 0.24
  23. Yan‐Shen Shan · 2 shared papers, 2011–2024 · strength 0.24
  24. Min‐Chuan Huang · 2 shared papers, 2018–2021 · strength 0.23
  25. Syue‐Ting Chen · 2 shared papers, 2018–2021 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.